NeuroSense Completes Health Canada Meeting for ALS Drug
Ticker: NRSNW · Form: 6-K · Filed: Jun 26, 2025 · CIK: 1875091
Sentiment: neutral
Topics: regulatory-update, drug-development, als
TL;DR
NeuroSense met with Health Canada on PrimeC for ALS, aiming for fast-track approval.
AI Summary
NeuroSense Therapeutics Ltd. announced on June 26, 2025, that it has completed a pre-New Drug Submission (pre-NDS) meeting with Health Canada for PrimeC, a potential treatment for ALS. The company is pursuing an expedited approval pathway, the Notice of Compliance with Conditions (NOC/c), and is currently finalizing the official meeting minutes with Health Canada.
Why It Matters
This meeting is a crucial step towards potential expedited approval of PrimeC for ALS patients, offering hope for a new treatment option.
Risk Assessment
Risk Level: medium — The outcome of regulatory meetings and the expedited approval process introduce inherent uncertainties.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- Health Canada (company) — Regulatory Body
- PrimeC (drug) — Potential ALS Treatment
- ALS (disease) — Target Condition
FAQ
What is the status of NeuroSense Therapeutics' PrimeC drug with Health Canada?
NeuroSense Therapeutics Ltd. has completed its pre-New Drug Submission (pre-NDS) meeting with Health Canada regarding the potential early approval of PrimeC for the treatment of ALS.
What is the specific regulatory pathway NeuroSense is pursuing for PrimeC in Canada?
NeuroSense is pursuing an expedited approval pathway under the Notice of Compliance with Conditions (NOC/c).
When did NeuroSense Therapeutics file this report?
This report was filed as of June 26, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
What is the SEC file number for NeuroSense Therapeutics Ltd.?
The SEC file number for NeuroSense Therapeutics Ltd. is 001-41084.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 26, 2025 regarding NeuroSense Therapeutics Ltd. (NRSNW).